OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
April 20, 2023
Gregor Kawaletz, head of Oral Solid Dose Business Unit at Recipharm, discusses the immediate future of oral biologics
April 18, 2023
Moderna and Merck reported that a combination therapy involving pembrolizumab and an mRNA demonstrated a 44% reduction in recurrence or death in cancer patients compared to non-combination treatments.
April 15, 2023
Lipids aren’t the only important ingredients influencing stability and in vivo performance.
The recent success of mRNA vaccines has opened the door for further and future development of nucleic acid-based therapies.
Actions combatting the next pandemic must be diverse, reliable, and sustainable.
Unique solutions are required to protect inherently unstable messenger RNA.
This article reviews a range of techniques available for separative analysis of mRNA therapeutics, their associated impurities, and delivery vehicles.
Considerable efforts have been made over the years to resolve the key issues of stability and delivery of RNA-based therapeutics.
The complexity of the RNA production process creates challenges.
April 14, 2023
FDA has granted fast track designation to Caribou Biosciences for its allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma.